Myriad Genetics (MYGN) Return on Invested Capital (2011 - 2026)

Myriad Genetics has disclosed Return on Invested Capital across 16 years of filings, most recently posting 0.01% for Q1 2026.

• In Q1 2026, Return on Invested Capital fell 1.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (down 1.0% YoY), while the FY2025 annual figure was 0.01%, changed 0.0% from the prior year.
• Return on Invested Capital fell to 0.01% in Q1 2026, from 0.01% in the prior quarter.
• Over the last five years, Return on Invested Capital for MYGN reached as high as 0.0% in Q1 2022 and fell as low as 0.01% in Q3 2025.
• The 5-year median for Return on Invested Capital is 0.0% (2024), against an average of 0.0%.
• Annual changes were most pronounced in 2022 — Return on Invested Capital changed 0 bps — and 2025, when it decreased 1 bps.
• A 5-year view of Return on Invested Capital shows it stood at 0.0% in 2022, then sank by 169 bps to 0.0% in 2023, then surged by 50 bps to 0.0% in 2024, then tumbled by 335 bps to 0.01% in 2025, then fell by 12 bps to 0.01% in 2026.
• According to Business Quant data, Return on Invested Capital over the past three periods registered 0.01%, 0.01%, and 0.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.